Narwhal Capital Management Pfizer Inc Transaction History

Narwhal Capital Management

$1.09 Billion
Q3 2024

A detailed history of Narwhal Capital Management transactions in Pfizer Inc stock. As of the latest transaction made, Narwhal Capital Management holds 20,545 shares of PFE stock, worth $548,962. This represents 0.05% of its overall portfolio holdings.

Number of Shares

20,545

Previous 49,428 58.43%

Holding current value

$548,962

Previous $1.38 Million 57.02%

% of portfolio

0.05%

Previous 0.13%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 22, 2024	SELL	$27.7 - $31.39 $800,059 - $906,637	-28,883 Reduced 58.43%	20,545 $594,000
Q2 2024 Aug 05, 2024	SELL	$25.26 - $29.6 $785,055 - $919,938	-31,079 Reduced 38.6%	49,428 $1.38 Million
Q1 2024 Apr 26, 2024	SELL	$25.89 - $29.73 $1.46 Million - $1.67 Million	-56,252 Reduced 41.13%	80,507 $2.23 Million
Q4 2023 Jan 24, 2024	SELL	$26.13 - $33.94 $689,649 - $895,778	-26,393 Reduced 16.18%	136,759 $3.94 Million
Q3 2023 Oct 27, 2023	SELL	$32.09 - $37.51 $517,547 - $604,961	-16,128 Reduced 9.0%	163,152 $5.41 Million
Q2 2023 Aug 02, 2023	SELL	$36.12 - $41.79 $432,320 - $500,184	-11,969 Reduced 6.26%	179,280 $6.58 Million
Q1 2023 May 01, 2023	SELL	$39.39 - $51.28 $1.12 Million - $1.45 Million	-28,367 Reduced 12.92%	191,249 $7.8 Million
Q4 2022 Jan 30, 2023	SELL	$41.75 - $54.5 $2.36 Million - $3.09 Million	-56,636 Reduced 20.5%	219,616 $11.3 Million
Q3 2022 Oct 31, 2022	SELL	$43.76 - $53.42 $416,507 - $508,451	-9,518 Reduced 3.33%	276,252 $12.1 Million
Q2 2022 Aug 01, 2022	BUY	$46.53 - $55.17 $4.21 Million - $4.99 Million	90,419 Added 46.29%	285,770 $15 Million
Q1 2022 Apr 26, 2022	BUY	$45.75 - $56.69 $226,188 - $280,275	4,944 Added 2.6%	195,351 $10.1 Million
Q4 2021 Jan 26, 2022	BUY	$41.32 - $61.25 $713,555 - $1.06 Million	17,269 Added 9.97%	190,407 $11.2 Million
Q3 2021 Oct 22, 2021	BUY	$39.25 - $50.42 $1.04 Million - $1.34 Million	26,510 Added 18.08%	173,138 $7.45 Million
Q2 2021 Jul 29, 2021	BUY	$35.91 - $40.68 $30,343 - $34,374	845 Added 0.58%	146,628 $5.74 Million
Q1 2021 Apr 23, 2021	SELL	$33.49 - $37.77 $203,418 - $229,414	-6,074 Reduced 4.0%	145,783 $5.28 Million
Q4 2020 Feb 02, 2021	SELL	$33.47 - $42.56 $247,878 - $315,199	-7,406 Reduced 4.65%	151,857 $5.59 Million
Q3 2020 Oct 26, 2020	SELL	$31.75 - $37.25 $587,343 - $689,087	-18,499 Reduced 10.41%	159,263 $5.85 Million
Q2 2020 Jul 22, 2020	SELL	$30.12 - $36.54 $556,979 - $675,697	-18,492 Reduced 9.42%	177,762 $5.81 Million
Q1 2020 Apr 30, 2020	BUY	$27.03 - $38.62 $122,526 - $175,064	4,533 Added 2.36%	196,254 $6.41 Million
Q4 2019 Jan 31, 2020	BUY	$32.92 - $37.36 $276,132 - $313,375	8,388 Added 4.58%	191,721 $7.51 Million
Q3 2019 Oct 31, 2019	SELL	$32.49 - $42.13 $58,806 - $76,255	-1,810 Reduced 0.98%	183,333 $6.59 Million
Q2 2019 Jul 30, 2019	BUY	$36.98 - $41.52 $109,571 - $123,023	2,963 Added 1.63%	185,143 $8.02 Million
Q1 2019 Apr 12, 2019	SELL	$37.5 - $41.2 $53,137 - $58,380	-1,417 Reduced 0.77%	182,180 $7.74 Million
Q4 2018 Jan 15, 2019	SELL	$38.47 - $43.86 $98,098 - $111,843	-2,550 Reduced 1.37%	183,597 $8.01 Million
Q3 2018 Oct 23, 2018	SELL	$34.47 - $41.81 $8,962 - $10,870	-260 Reduced 0.14%	186,147 $8.2 Million
Q2 2018 Jul 19, 2018	SELL	$32.98 - $35.16 $37,300 - $39,765	-1,131 Reduced 0.6%	186,407 $6.76 Million
Q1 2018 Apr 17, 2018	BUY	$31.91 - $37.02 $526,770 - $611,126	16,508 Added 9.65%	187,538 $6.66 Million
Q4 2017 Jan 23, 2018	BUY	$33.26 - $35.29 $241,135 - $255,852	7,250 Added 4.43%	171,030 $6.2 Million
Q3 2017 Oct 17, 2017	BUY	$31.0 - $34.15 $5.08 Million - $5.59 Million	163,780	163,780 $5.85 Million

Others Institutions Holding PFE

# of Institutions

3,260

Shares Held

3.73B

Call Options Held

73.5M

Put Options Held

108M

View Full List

About PFIZER INC

Ticker PFE
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 5,612,349,952
Market Cap $150B
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...

More about PFE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Narwhal Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Narwhal Capital Management with notifications on news.

Account

Narwhal Capital Management Pfizer Inc Transaction History